Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Intellia

CRISPR Stock Intellia Therapeutics Thinks It Has The Cure To A Swelling Disorder

NTLA stock rose Monday after Intellia said its CRISPR-based gene-editing drug almost totally eliminated attacks in a swelling disease.

Investors Business Daily

Alzheimer’s-Like Diseases Can Affect the Body — Scientists Are Working to Find Out Why

Amyloid plaque can build up in body organs other than the brain, and today's treatments have a ways to go.

Inverse

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing

The FDA cleared Intellia to begin testing its CRISPR gene-editing technology in people on Thursday, leading NTLA stock to jump.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.

Investors Business Daily

Intellia, Other CRISPR Stocks Hammered On Safety Concerns In New Gene-Editing Test

Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.

Investors Business Daily

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

Benzinga

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.

Investors Business Daily

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis. Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data,…

Benzinga

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

Benzinga

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

StockNews.com

Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer

Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has

Benzinga

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Eight months after

Benzinga

Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test

Intellia successfully lowered a problematic protein in patients with a liver disease on Monday, but NTLA stock fell on a patent decision.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Intellia Therapeutics Pops After Forging A Cancer Deal Worth Nearly $1 Billion

Intellia stock surged Tuesday after the CRISPR gene-editing company forged a cancer deal with Onk Therapeutics worth nearly $1 billion.

People

Mangeet Kaur BounsMangeet

472 stories

Gareth Morgan

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

Regeneron Pharmaceuticals Inc

Ginkgo Bioworks Holdings Inc

23 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.